Hypothesis

Emodin attenuates age‑associated neuroinflammation and cognitive impairment not by acting directly on the brain, but by remodeling the gut microenvironment: it suppresses NLRP3 inflammasome activity and EGFR/MAPK signaling in gut‑resident macrophages and epithelial cells, thereby reducing SASP production, restoring barrier integrity, and shifting the microbiota toward a youthful composition. The resulting decline in systemic microbial‑derived danger signals (e.g., LPS, DAMPs) curtails microglial activation in the hippocampus and prefrontal cortex, preserving synaptic function.

Mechanistic Rationale

1. NLRP3 inhibition in gut immune cells – Emodin’s proven blockade of NLRP3 in macrophages lowers IL‑1β and caspase‑1 release (1). In the aged gut, IL‑1β drives epithelial senescence through NF‑κB‑mediated p16^INK4a^ induction; reducing this cytokine should diminish senescent epithelial burden.
2. EGFR/MAPK suppression – By attenuating EGFR and Ras expression, emodin skews macrophages away from an M1 phenotype (4). Chronic EGFR signaling in intestinal stem cells promotes proliferative stress and premature senescence; its inhibition therefore limits the emergence of senescent progenitors.
3. Indirect CDK/cyclin D1 modulation – Although emodin does not directly inhibit CDKs, related anthraquinones (e.g., aloe‑emodin) downregulate cyclin D1 via AKT/ERK pathways (6). We posit that emodin similarly attenuates cyclin D1 transcription in gut epithelium, fostering a G1 arrest that permits clearance of damaged cells rather than maladaptive senescence.
4. Microbiota‑mediated inflammaging – Emodin reshapes microbial communities, increasing beneficial taxa (e.g., Akkermansia, Lactobacillus) and decreasing pathobionts that produce LPS (2, 3). A youthful microbiota yields lower circulating endotoxin, decreasing systemic TLR4 activation and downstream neuroinflammatory cascades.
5. Gut‑brain signaling – Reduced luminal LPS and microbial metabolites lessen hepatic acute‑phase response and circulating IL‑6/TNF‑α, limiting their transport across the blood‑brain barrier. Consequently, hippocampal microglia exhibit lower Iba1 expression and reduced NLRP3 inflammasome activation, preserving LTP and memory.

Testable Predictions

• Prediction 1: In 24‑month‑old mice, 4‑week oral emodin (50 mg/kg/day) will decrease p16^INK4a^ and SA‑β‑gal positivity in colonic epithelium by ≥30% relative to vehicle.
• Prediction 2: Emodin treatment will shift fecal microbiota composition toward increased relative abundance of Akkermansia muciniphila and decreased Enterobacteriaceae (measured by 16S rRNA sequencing).
• Prediction 3: Serum LPS and IL‑6 levels will drop ≥25% after emodin, correlating with reduced hippocampal Iba1^+^ microglial density.
• Prediction 4: Treated aged mice will show improved performance in the Morris water maze (escape latency ↓20%) and novel object recognition (discrimination index ↑15%) compared with controls.
• Falsification: If emodin fails to reduce gut epithelial senescence or microbiota dysbiosis, yet still improves cognition, the gut‑centric mechanism is refuted; conversely, if gut improvements occur without cognitive benefit, the gut‑brain link is insufficient.

Experimental Design (brief)

• Groups: Young (3 mo), aged vehicle, aged emodin, aged emodin + gut‑specific antibiotic cocktail (to test microbiota necessity).
• Readouts: Colon histology (p16, SA‑β‑gal), flow cytometry for CD45^+^F4/80^+^NLRP3^+^ macrophages, 16S sequencing, serum cytokine/LPS ELISA, brain immunohistochemistry (Iba1, NLRP3), behavioral batteries.
• Analysis: Two‑way ANOVA with post‑hoc Tukey; mediation analysis to test whether microbiota shifts mediate the effect of emodin on neuroinflammation.

By integrating emodin’s known anti‑inflammasome, EGFR/MAPK, and microbiota‑modulating actions into a unified gut‑centric model of inflammaging, this hypothesis provides a clear, falsifiable roadmap for translating a natural compound into a therapy that targets the microbiome‑brain axis in aging.